Rosetta Genomics Ltd. Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2017-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2017-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2017-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2017-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2017-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 2.89M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 796.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -10.59M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | $2.89M | (m) | $796.00K | $-10.59M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $3.16M | $2.04M | $859.00K | $-12.63M | $23.00K | 154.78% | 42.13% | -549.35× | Reported |
| 2016-06-30 | $3.05M | (m) | $931.00K | $-12.79M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $2.96M | $2.88M | $1.02M | $-12.94M | $27.00K | 102.82% | 35.34% | -479.41× | Reported |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $1.93M | $1.33M | $943.00K | $-14.25M | $39.00K | 145.21% | 71.06% | -365.44× | Reported |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $1.74M | $405.00K | $893.00K | $-13.35M | $15.00K | 430.62% | 220.49% | -889.80× | Reported |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $1.25M | $201.00K | $549.00K | $-8.27M | $31.00K | 620.40% | 273.13% | -266.68× | Reported |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $3.39M | $103.00K | $604.00K | $-8.78M | $19.00K | 3287.38% | 586.41% | -461.95× | Reported |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $5.71M | $279.00K | $737.00K | $-13.91M | $36.00K | 2045.52% | 264.16% | -386.53× | Reported |
| 2009-12-31 | $6.55M | $150.00K | $1.37M | $14.80M | (m) | 4368.00% | 914.67% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.